Literature DB >> 18424949

Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results.

Christian Plathow1, Philip Aschoff, Mathias Philip Lichy, Susanne Eschmann, Thomas Hehr, Ingo Brink, Claus D Claussen, Christina Pfannenberg, Heinz-Peter Schlemmer.   

Abstract

OBJECTIVE: To evaluate and compare positron emission tomography/computed tomography (PET/CT) with whole-body magnetic resonance imaging (wbMRI) in the correct staging of patients with advanced nonsmall cell lung cancer (NSCLC).
MATERIALS AND METHODS: Fifty-two patients with an NSCLC stage IIIa or IIIb (36 males and 16 females) were included in this study. Patients were referred to our department for restaging. Within 1 week PET/CT and wbMRI were performed in all patients. Images were examined independently by 2 experienced physicians from the Department of Nuclear Medicine and Radiology. Afterward, consensus reading was performed. In 22 patients, surgery served as gold standard, whereas in 30 patients, follow-up controls (after 2 months) were performed.
RESULTS: The use of wbMRI correctly T-staged all patients. Especially volume interpolated breathhold examination sequence correctly T-staged all tumors. PET/CT did not correctly stage chest wall infiltration in 4 cases [sensitivity 92.3% (P < 0.05 to wbMRI)/specificity 100%], verified by surgery. PET/CT correctly N-staged 51 patients (sensitivity 96.1%/specificity 100%). WbMRI showed a significant tendency to understage N-status [sensitivity 88.5% (P < 0.05)/specificity 96.1%]. Different N-status by PET/CT changed operability in 4 patients. In 2 patients, distant metastases were detected by both techniques.
CONCLUSION: In the correct staging of advanced NSCLC, PET/CT has advantages in N-staging. This is of high relevance for therapy planning. WbMRI especially using volume interpolated breathhold examination sequences, has certain advantages in T-staging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18424949     DOI: 10.1097/RLI.0b013e318163273a

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  13 in total

1.  Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.

Authors:  Joshua H Finkle; Stephanie Y Jo; Mark K Ferguson; Hai-Yan Liu; Chenpeng Zhang; Xuee Zhu; Cindy Yuan; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-07       Impact factor: 9.236

Review 2.  Prognostic value of metabolic tumor burden in lung cancer.

Authors:  Piotr Obara; Yonglin Pu
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

3.  Multimodality molecular imaging of the lung.

Authors:  Delphine L Chen; Paul E Kinahan
Journal:  Clin Transl Imaging       Date:  2014-10-16

4.  Quantification of metabolic tumor activity and burden in patients with non-small-cell lung cancer: Is manual adjustment of semiautomatic gradient-based measurements necessary?

Authors:  Piotr Obara; Haiping Liu; Kristen Wroblewski; Chen-Peng Zhang; Peng Hou; Yulei Jiang; Ping Chen; Yonglin Pu
Journal:  Nucl Med Commun       Date:  2015-08       Impact factor: 1.690

5.  Consistency and prognostic value of preoperative staging and postoperative pathological staging using 18F-FDG PET/MRI in patients with non-small cell lung cancer.

Authors:  Akiko Kajiyama; Kimiteru Ito; Hirokazu Watanabe; Sunao Mizumura; Shun-Ichi Watanabe; Yasushi Yatabe; Tatsuya Gomi; Masahiko Kusumoto
Journal:  Ann Nucl Med       Date:  2022-10-20       Impact factor: 2.258

6.  Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer.

Authors:  Julian Kirchner; Lino M Sawicki; Felix Nensa; Benedikt M Schaarschmidt; Henning Reis; Marc Ingenwerth; Simon Bogner; Clemens Aigner; Christian Buchbender; Lale Umutlu; Gerald Antoch; Ken Herrmann; Philipp Heusch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-03       Impact factor: 9.236

7.  Whole-body MRI using a sliding table and repositioning surface coil approach.

Authors:  Taro Takahara; Thomas Kwee; Satoshi Kibune; Reiji Ochiai; Tetsuro Sakamoto; Tetsu Niwa; Marc Van Cauteren; Peter Luijten
Journal:  Eur Radiol       Date:  2009-12-08       Impact factor: 5.315

Review 8.  Clinical applications of PET/MRI: current status and future perspectives.

Authors:  Felix Nensa; Karsten Beiderwellen; Philipp Heusch; Axel Wetter
Journal:  Diagn Interv Radiol       Date:  2014 Sep-Oct       Impact factor: 2.630

9.  Conspicuity of FDG-Avid Osseous Lesions on PET/MRI Versus PET/CT: a Quantitative and Visual Analysis.

Authors:  Tyler J Fraum; Kathryn J Fowler; Jonathan McConathy
Journal:  Nucl Med Mol Imaging       Date:  2016-02-19

Review 10.  Magnetic resonance imaging for N staging in non-small cell lung cancer: A systematic review and meta-analysis.

Authors:  Yuanyuan Zhang; Qin Qin; Baosheng Li; Juan Wang; Kun Zhang
Journal:  Thorac Cancer       Date:  2015-01-08       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.